Home Current Issue Previous Issues Published Ahead-of-Print Collections Videos For Authors Journal Info
Skip Navigation LinksHome > October 2004 - Volume 240 - Issue 4 > Alvimopan, a Novel, Peripherally Acting μ Opioid Antagonist:...
Text sizing:
A
A
A
Annals of Surgery:
Original Articles and Discussions

Alvimopan, a Novel, Peripherally Acting μ Opioid Antagonist: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Major Abdominal Surgery and Postoperative Ileus

Wolff, Bruce G. MD*; Michelassi, Fabrizio MD†; Gerkin, Todd M. MD‡; Techner, Lee DPM§; Gabriel, Kathie RN§; Du, Wei PhD§; Wallin, Bruce A. MD§; Alvimopan Postoperative Ileus Study Group

Collapse Box

Abstract

Objective: To demonstrate that alvimopan (6 or 12 mg) accelerates recovery of gastrointestinal (GI) function in patients undergoing laparotomy for bowel resection or radical hysterectomy.

Summary Background Data: Postoperative ileus (POI) following laparotomy may increase morbidity and extend hospitalization. Opioids can contribute to the duration of POI. Alvimopan is a novel opioid receptor antagonist in development for the management of POI.

Methods: A total of 510 patients scheduled for bowel resection or radical hysterectomy were randomized (1:1:1) to receive alvimopan 6 mg, alvimopan 12 mg, or placebo orally ≥2 hours before surgery, then twice a day (b.i.d.) until hospital discharge or for up to 7 days. The primary efficacy end point was a composite of time to recovery of upper and lower GI function. An associated secondary end point was time to hospital discharge order written.

Results: The modified intent-to-treat population included 469 patients (451 bowel resection and 18 radical hysterectomy patients). Time to recovery of GI function was accelerated for the alvimopan 6 mg (hazard ratio [HR] = 1.28; P < 0.05) and 12 mg (HR = 1.54; P < 0.001) groups with a mean difference of 15 and 22 hours, respectively, compared with placebo. The time to hospital discharge order written was also accelerated in the alvimopan 12 mg group (HR = 1.42; P = 0.003) with a mean difference of 20 hours compared with placebo. The incidence of adverse events was similar among treatment groups.

Conclusions: Alvimopan accelerated GI recovery and time to hospital discharge order written compared with placebo in patients undergoing laparotomy and was well tolerated.

© 2004 Lippincott Williams & Wilkins, Inc.

Login